STTK - NASDAQ
Shattuck Labs, Inc.
$4.89
+0.43%Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
At a Glance
Live Snapshotsttk
EPS
Last Annual Value
-0.70
3-Year CAGR
34%
5-Year CAGR
4%
10-Year CAGR
-4%
Shattuck Labs, Inc. Competitors Analysis of EPS
| Company | EPS | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Shattuck Labs, Inc. NASDAQ:STTK | -0.70 | N/A | N/A | N/A | |
 ImageneBio Inc NASDAQ:IMA | -10.76 | N/A | N/A | N/A | |
 Adverum Biotechnologies, Inc. NASDAQ:ADVM | -6.62 | N/A | N/A | N/A | |
 ALX Oncology Holdings Inc. NASDAQ:ALXO | -1.90 | N/A | N/A | N/A | |
 Spruce Biosciences, Inc. NASDAQ:SPRB | -50.83 | N/A | N/A | N/A | |
 Unicycive Therapeutics, Inc. NASDAQ:UNCY | -1.67 | N/A | N/A | N/A | |
 Pliant Therapeutics, Inc. NASDAQ:PLRX | -2.43 | N/A | N/A | N/A | |
 Whitehawk Therapeutics Inc NASDAQ:WHWK | -0.33 | N/A | N/A | N/A | |
 Metagenomi, Inc. Common Stock NASDAQ:MGX | -2.36 | N/A | N/A | N/A | |
 Ovid Therapeutics Inc. NASDAQ:OVID | -0.24 | N/A | N/A | N/A | |
 Kalaris Therapeutics Inc NASDAQ:KLRS | -2.85 | N/A | N/A | N/A |
Shattuck Labs, Inc. Fair Value Envelope
Related Guides
Continue your STTK research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.